Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/HDP1 stock hub

FRA/HDP1 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/HDP1is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.6B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/HDP1

In the news

Latest news · FRA/HDP1

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-42.4

P25 n/aP50 n/aP75 n/a

ROIC-83.1

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/HDP1 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

179

Groups with data

Currency

USD

Showing 179 of 179 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	711
Employees Change	102%
Employees Change Percent	16.75
Enterprise value	EUR 8.3B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 8.6B
Price	EUR 61.56
Price currency	EUR
Rev Per Employee	758,746x
Sic	2836
Symbol	fra/HDP1
Website	https://arrowheadpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.02%
EV Earnings	-31.75x
EV/FCF	-187.81x
EV/Sales	15.68x
FCF yield	-0.51%
P/B ratio	16.65x
P/S ratio	16.03x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-35.67%
EBITDA Margin	-31.6%
Gross margin	100%
Gross Profit	EUR 539.5M
Gross Profit Growth	14.09%
Gross Profit Growth Q	-86.41%
Gross Profit Growth3 Y	31.62%
Gross Profit Growth5 Y	47.49%
Net Income	EUR -261M
Pretax Margin	-40.56%
Profit Margin	-48.38%
Profit Per Employee	EUR -367,059
ROA	-7.22
Roa5y	-16.64
ROCE	-11.25
ROE	-42.37
Roe5y	-76.13
ROIC	-83.07
Roic5y	-116.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	28.92%
Cagr15y	20.77%
Cagr1y	444.19%
Cagr20y	0.42%
Cagr3y	20.02%
Cagr5y	2.9%
FCF Growth Q	-82%
OCF Growth Q	-81.65%
Revenue Growth	14.09x
Revenue Growth Q	-86.41x
Revenue Growth3 Y	31.62x
Revenue Growth5 Y	47.49x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.32
Assets	EUR 2B
Cash	EUR 1.5B
Current Assets	EUR 1.6B
Current Liabilities	EUR 250.3M
Debt	EUR 1.2B
Debt Equity	EUR 2.29
Debt FCF	EUR -26.99
Equity	EUR 519.4M
Interest Coverage	-2.4
Liabilities	EUR 1.4B
Long Term Assets	EUR 407.2M
Long Term Liabilities	EUR 1.2B
Net Cash	EUR 356.3M
Net Cash By Market Cap	EUR 4.12
Net Cash Growth	15.79%
Net Debt Equity	EUR -0.69
Tangible Book Value	EUR 527.3M
Tangible Book Value Per Share	EUR 3.75

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.23
Net Working Capital	EUR -166.3M
Quick ratio	6.1
Working Capital	EUR 1.3B
Working Capital Turnover	EUR 0.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.83%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,167.52%
1Y total return	443.55%
200-day SMA	42.09
3Y total return	72.9%
50-day SMA	55.4
50-day SMA vs 200-day SMA	50over200
5Y total return	15.39%
All Time High	75.22
All Time High Change	-17.04%
All Time High Date	2021-06-28
All Time Low	1.16
All Time Low Change	5,265.43%
All Time Low Date	2016-12-19
ATR	2.57
Ch YTD	7.77
High	66.16
High52	67.36
High52 Date	2026-05-06
High52ch	-8.61%
Low	61.54
Low52	11.54
Low52 Date	2025-05-08
Low52ch	433.68%
Ma50ch	12.64%
Price vs 200-day SMA	48.26%
RSI	53.63
RSI Monthly	71.94
RSI Weekly	70.54
Sharpe ratio	2.7x
Sortino ratio	5.22
Total Return	-9.83%
Tr YTD	7.77
Tr15y	1,595.65%
Tr1m	18.63%
Tr1w	-4.27%
Tr3m	12.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -192.4M
Operating margin	-35.67

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	122,037,310%
Net Borrowing	488,217,513.3
Shares Insiders	3.32%
Shares Institutions	74.75%
Shares Qo Q	1.22%
Shares Yo Y	9.83%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -103.2M
Average Volume	48.15x
Bv Per Share	3.79
CAPEX	EUR -12.6M
Ch10y	1,167.5
Ch15y	1,595.7
Ch1m	18.63
Ch1w	-4.27
Ch1y	443.6
Ch20y	8.71
Ch3m	12.64
Ch3y	72.9
Ch5y	15.39
Ch6m	85.11
Change	-6.81%
Change From Open	-6.95
Close	66.06
Days Gap	0.15
Depreciation Amortization	21,510,252.1
Earnings Date	2026-08-05
EBIT	EUR -192.4M
EBITDA	EUR -170.4M
EPS	EUR -1.88
F Score	2
FCF	EUR -44.1M
FCF EV Yield	-0.53x
Financing CF	643,499,306
Fiscal Year End	September
Founded	2,003
Income Tax	EUR 17M
Investing CF	-610,592,210
Is Primary Listing	0
Last Earnings Date	2026-02-05
Last Report Date	2026-03-31
Last Split Date	2011-11-17
Last Split Type	Reverse
Ma150	49.58
Ma150ch	25.86%
Ma20	60.95
Ma20ch	2.39%
Net CF	2,435,378
Next Earnings Date	2026-08-05
Open	66.16
Position In Range	0.43
Ppne	354,122,498.6
Price Date	2026-05-08
Ptbv Ratio	16.4
Relative Volume	2.54x
Revenue	539,468,406x
SBC By Revenue	10.96x
Share Based Comp	59,124,708
Tax By Revenue	3.15x
Tr20y	8.71%
Tr6m	85.11%

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/HDP1 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/HDP1 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/HDP1?

Insider, institutional, and short-interest positioning.

Institutional ownership

+74.8%

Share of float held by funds and institutions

Insider ownership

+3.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+9.8%

Negative means the company is buying back shares.

Technical

FRA/HDP1 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.6

Neutral momentum band

Price vs 200-day MA

+48.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

2.70

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/HDP1

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/HDP1 stock rating?

fra/HDP1 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/HDP1 analysis?

The full report lives at /stocks/fra/HDP1/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/HDP1?

The latest report frames fra/HDP1 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/HDP1 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.